Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Cimzia® (certolizumab pegol) – New indication

September 13, 2024 - The FDA approved UCB’s Cimzia (certolizumab pegol), for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.

Download PDF

Rx navigation